Literature DB >> 22169090

Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status.

Xian Yu1, Rafael Prados-Rosales, Elisabeth R Jenny-Avital, Katherine Sosa, Arturo Casadevall, Jacqueline M Achkar.   

Abstract

Despite the complexity of tuberculosis (TB) serology, antibodies (Abs) remain attractive biomarkers for TB. Recent evidence of a mycobacterial capsule that consists mainly of the polysaccharides arabinomannan (AM) and glucan provides new options for serologic targets. For this study, Ab responses to AM and glucan for 47 U.S. TB patients (33 HIV negative [HIV(-)], 14 HIV positive [HIV(+)]), 42 healthy controls, and 38 asymptomatic HIV(+) controls were evaluated by enzyme-linked immunosorbent assays (ELISAs). The results were compared with Ab responses to the mycobacterial glycolipid cell wall antigen lipoarabinomannan (LAM) and to the proteins malate synthase (MS) and MPT51. We found that the main immunoglobulin (Ig) isotype response to polysaccharides was IgG, predominantly of subclass IgG2. IgG responses to AM were significantly higher for HIV(-) and HIV(+) TB cases than for controls (P, <0.0001 and <0.01, respectively); significantly higher for HIV(-) than for HIV(+) TB cases (P, <0.01); and significantly higher in sputum smear-positive than smear-negative patients in both HIV(-) and HIV(+) cases (P, 0.01 and 0.02, respectively). In both TB groups, titers of Ab to glucan were significantly lower than titers of Ab to AM (P, <0.0001). IgG responses to AM and MS or to AM and MPT51 did not correlate with each other in HIV(-) TB patients, while they correlated significantly in HIV(+) TB patients (P, 0.01 and 0.05, respectively). We conclude that Ab responses to AM could contribute to the serodiagnosis of TB, especially for HIV(-) TB patients. This study also provides new and important insights into the differences in the profiles of Abs to mycobacterial antigens between HIV(-) and HIV(+) TB patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169090      PMCID: PMC3272928          DOI: 10.1128/CVI.05550-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  49 in total

1.  Circulating antibodies to lipoarabinomannan in relation to sputum microscopy, clinical features and urinary anti-lipoarabinomannan detection in pulmonary tuberculosis.

Authors:  Tsigeweini Asgedom Tessema; Gunnar Bjune; Beston Hamasur; Stefan Svenson; Heidi Syre; Bjarne Bjorvatn
Journal:  Scand J Infect Dis       Date:  2002

Review 2.  The capsule of Mycobacterium tuberculosis and its implications for pathogenicity.

Authors:  M Daffé; G Etienne
Journal:  Tuber Lung Dis       Date:  1999

3.  Correlation between serum and plasma antibody titers to mycobacterial antigens.

Authors:  Michael Siev; Xian Yu; Rafael Prados-Rosales; Frank T Martiniuk; Arturo Casadevall; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

4.  WHO recommends against inaccurate tuberculosis tests.

Authors:  Kelly Morris
Journal:  Lancet       Date:  2011-01-08       Impact factor: 79.321

5.  Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.

Authors:  C P Taborda; A Casadevall
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

6.  Homogeneity of antibody responses in tuberculosis patients.

Authors:  K Samanich; J T Belisle; S Laal
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo.

Authors:  J R Schwebach; A Casadevall; R Schneerson; Z Dai; X Wang; J B Robbins; A Glatman-Freedman
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

8.  Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis.

Authors:  K M Samanich; M A Keen; V D Vissa; J D Harder; J S Spencer; J T Belisle; S Zolla-Pazner; S Laal
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

9.  Glucan is a component of the Mycobacterium tuberculosis surface that is expressed in vitro and in vivo.

Authors:  J Reid Schwebach; Aharona Glatman-Freedman; Leslie Gunther-Cummins; Zhongdong Dai; John B Robbins; Rachel Schneerson; Arturo Casadevall
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 10.  Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response.

Authors:  Jacqueline M Achkar; Elizabeth R Jenny-Avital
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

View more
  32 in total

Review 1.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

2.  SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.

Authors:  Arturo Casadevall; Michael J Joyner; Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

3.  Serological diagnostic assays for HIV-associated tuberculosis in sub-Saharan Africa?

Authors:  Stephen D Lawn
Journal:  Clin Vaccine Immunol       Date:  2014-04-16

4.  Capsular glycan recognition provides antibody-mediated immunity against tuberculosis.

Authors:  Tingting Chen; Caroline Blanc; Yanyan Liu; Elise Ishida; Sarah Singer; Jiayong Xu; Maju Joe; Elizabeth R Jenny-Avital; John Chan; Todd L Lowary; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

5.  Antibodies against Mycobacterial proteins as biomarkers for HIV-associated smear-negative tuberculosis.

Authors:  Michael Siev; Douglas Wilson; Supreet Kainth; Victoria O Kasprowicz; Catherine M Feintuch; Elizabeth R Jenny-Avital; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

6.  The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.

Authors:  Rafael Prados-Rosales; Leandro J Carreño; Brian Weinrick; Ana Batista-Gonzalez; Aarona Glatman-Freedman; Jiayong Xu; John Chan; William R Jacobs; Steven A Porcelli; Arturo Casadevall
Journal:  J Infect Dis       Date:  2016-04-18       Impact factor: 5.226

Review 7.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

8.  Effects of anticoagulants and Ficoll on human serum antibody reactivities and functions against Mycobacterium tuberculosis.

Authors:  Nicholas J Gadsden; Yanyan Liu; Stephanie Gati; Tingting Chen; Elizabeth R Jenny-Avital; Jacqueline M Achkar
Journal:  Tuberculosis (Edinb)       Date:  2020-01-10       Impact factor: 3.131

Review 9.  Advances in Diagnostic Assays for Tuberculosis.

Authors:  Stephen D Lawn
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-07       Impact factor: 6.915

Review 10.  Antibody responses to mycobacterial antigens in children with tuberculosis: challenges and potential diagnostic value.

Authors:  Jacqueline M Achkar; Anke Ziegenbalg
Journal:  Clin Vaccine Immunol       Date:  2012-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.